Targeted antigen delivery and activation of dendritic cells in vivo: Steps towards cost effective vaccines

Seminars in Immunology

Volumn 23, Issue 1, 2011, Pages 12-20

  Tacken, Paul J ^a   Figdor, Carl G ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Adjuvant; Cancer; Dendritic cell; Immunity; Targeting; Vaccine

Indexed keywords

ANTIGEN; CD40 ANTIGEN; DENDRITIC CELL VACCINE; FC RECEPTOR; IMMUNOLOGICAL ADJUVANT; RESIQUIMOD; TOLL LIKE RECEPTOR;

ANTIGEN EXPRESSION; CD8+ T LYMPHOCYTE; CELL ACTIVATION; CELL MATURATION; CELL SUBPOPULATION; CELL THERAPY; COST EFFECTIVENESS ANALYSIS; CROSS PRESENTATION; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DRUG ADMINISTRATION; DRUG TARGETING; HALF LIFE TIME; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOTHERAPY; IN VIVO STUDY; LANGERHANS CELL; NONHUMAN; PLASMACYTOID DENDRITIC CELL; REVIEW;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIGEN PRESENTATION; ANTIGENS; DENDRITIC CELLS; HUMANS; RECEPTORS, CELL SURFACE; VACCINES;

EID: 79952440284     PISSN: 10445323     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.smim.2011.01.001     Document Type: Review

References (125)

1. Tacken P.J., de Vries I.J., Torensma R., Figdor C.G. Dendritic-cell immunotherapy: from ex vivo loading to in vivo targeting. Nat Rev Immunol 2007, 7:790-802.
2. Snider D.P., Kaubisch A., Segal D.M. Enhanced antigen immunogenicity induced by bispecific antibodies. J Exp Med 1990, 171:1957-1963.
3. Young L.J., Wilson N.S., Schnorrer P., Proietto A., ten Broeke T., Matsuki Y., et al. Differential MHC class II synthesis and ubiquitination confers distinct antigen-presenting properties on conventional and plasmacytoid dendritic cells. Nat Immunol 2008, 9:1244-1252.
4. Hoeffel G., Ripoche A.C., Matheoud D., Nascimbeni M., Escriou N., Lebon P., et al. Antigen crosspresentation by human plasmacytoid dendritic cells. Immunity 2007, 27:481-492.
5. Di Pucchio T., Chatterjee B., Smed-Sorensen A., Clayton S., Palazzo A., Montes M., et al. Direct proteasome-independent cross-presentation of viral antigen by plasmacytoid dendritic cells on major histocompatibility complex class I. Nat Immunol 2008, 9:551-557.
6. + T cells after FcγRII-mediated uptake. J Exp Med 2006, 203:1629-1635.
7. Tel J., Lambeck A.J.A., Cruz L.J., Tacken P.J., de Vries I.J., Figdor C.G. Human plasmacytoid dendritic cells phagocytose, process, and present exogenous particulate antigen. J Immunol 2010, 184:4276-4283.
8. Dzionek A., Sohma Y., Nagafune J., Cella M., Colonna M., Facchetti F., et al. BDCA-2, a novel plasmacytoid dendritic cell-specific type II C-type lectin, mediates antigen capture and is a potent inhibitor of interferon α/β induction. J Exp Med 2001, 194:1823-1834.
9. Meyer-Wentrup F., Benitez-Ribas D., Tacken P.J., Punt C.J.A., Figdor C.G., de Vries I.J., et al. Targeting DCIR on human plasmacytoid dendritic cells results in antigen presentation and inhibits IFN-α production. Blood 2008, 111:4245-4253.
10. Zhang J., Raper A., Sugita N., Hingorani R., Salio M., Palmowski M.J., et al. Characterization of Siglec-H as a novel endocytic receptor expressed on murine plasmacytoid dendritic cell precursors. Blood 2006, 107:3600-3608.
11. Hochrein H., Shortman K., Vremec D., Scott B., Hertzog P., O'Keeffe M. Differential production of IL-12 IFN-α, and IFN-γ by mouse dendritic cell subsets. J Immunol 2001, 166:5448-5455.
12. Belz G.T., Behrens G.M., Smith C.M., Miller J.F., Jones C., Lejon K., et al. The CD8alpha(+) dendritic cell is responsible for inducing peripheral self-tolerance to tissue-associated antigens. J Exp Med 2002, 196:1099-1104.
13. + but not CD8-dendritic cells cross-prime cytotoxic T cells in vivo. J Exp Med 2000, 192:1685-1696.
14. + dendritic cell subset selectively endocytoses dying cells in culture and in vivo. J Exp Med 2002, 195:1289-1302.
15. Dudziak D., Kamphorst A.O., Heidkamp G.F., Buchholz V.R., Trumpfheller C., Yamazaki S., et al. Differential antigen processing by dendritic cell subsets in vivo. Science 2007, 315:107-111.
16. Boscardin S.B., Hafalla J.C.R., Masilamani R.F., Kamphorst A.O., Zebroski H.A., Rai U., et al. Antigen targeting to dendritic cells elicits long-lived T cell help for antibody responses. J Exp Med 2006, 203:599-606.
17. Corbett A.J., Caminschi I., McKenzie B.S., Brady J.L., Wright M.D., Mottram P.L., et al. Antigen delivery via two molecules on the CD8-dendritic cell subset induces humoral immunity in the absence of conventional " danger" Eur J Immunol 2005, 35:2815-2825.
18. Idoyaga J., Cheong C., Suda K., Suda N., Kim J.Y., Lee H., et al. Cutting edge: Langerin/CD207 receptor on dendritic cells mediates efficient antigen presentation on MHC I and II products in vivo. J Immunol 2008, 180:3647-3650.
19. Kato M., McDonald K.J., Khan S., Ross I.L., Vuckovic S., Chen K., et al. Expression of human DEC-205 (CD205) multilectin receptor on leukocytes. Int Immunol 2006, 18:857-869.
20. + dermal dendritic cells cross-present keratinocyte-derived antigens irrespective of the presence of Langerhans cells. J Exp Med 2009, 207:189-206.
21. + dermal dendritic cells play a critical role in Th effector cell differentiation after subcutaneous immunization. J Exp Med 2010, 207:953-961.
22. + dendritic cells. Nat Immunol 2009, 10:488-495.
23. + DCs. J Exp Med 2009, 206:3115-3130.
24. Robbins S., Walzer T., Dembele D., Thibault C., Defays A., Bessou G., et al. Novel insights into the relationships between dendritic cell subsets in human and mouse revealed by genome-wide expression profiling. Genome Biol 2008, 9:R17.
25. + dendritic cells. J Exp Med 2010, 207:1273-1281.
26. + dendritic cells. J Exp Med 2010, 207:1283-1292.
27. + dendritic cells (DCs) represent a unique myeloid DC subset that cross-presents necrotic cell antigens. J Exp Med 2010, 207:1247-1260.
28. + dendritic cells. J Exp Med 2010, 207:1261-1271.
29. + dendritic cells and a subset of monocytes. J Biol Chem 2008, 283:16693-16701.
30. Caminschi I., Proietto A.I., Ahmet F., Kitsoulis S., Shin Teh J., Lo J.C.Y., et al. The dendritic cell subtype-restricted C-type lectin Clec9A is a target for vaccine enhancement. Blood 2008, 112:3264-3273.
31. Sancho D., Mourao-Sa D., Joffre O.P., Schulz O., Rogers N.C., Pennington D.J., et al. Tumor therapy in mice via antigen targeting to a novel DC-restricted C-type lectin. J Clin Invest 2008, 118:2098-2110.
32. + T-cell compartment by antigen targeting to DNGR-1/CLEC9A. Eur J Immunol 2010, 40:1255-1265.
33. Dakappagari N., Maruyama T., Renshaw M., Tacken P., Figdor C., Torensma R., et al. Internalizing antibodies to the C-type lectins, L-SIGN and DC-SIGN, inhibit viral glycoprotein binding and deliver antigen to human dendritic cells for the induction of T cell responses. J Immunol 2006, 176:426-440.
34. Geijtenbeek T.B.H., Torensma R., van Vliet S.J., van Duijnhoven G.C.F., Adema G.J., van Kooyk Y., et al. Identification of DC-SIGN, a novel dendritic cell-specific ICAM-3 receptor that supports primary immune responses. Cell 2000, 100:575-585.
35. Kretz-Rommel A., Qin F., Dakappagari N., Torensma R., Faas S., Wu D., et al. In vivo targeting of antigens to human dendritic cells through DC-SIGN elicits stimulatory immune responses and inhibits tumor growth in grafted mouse models. J Immunother 2007, 30:715-726.
36. Pereira C.F., Torensma R., Hebeda K.M., Kretz-Rommel A., Faas S.J., Figdor C.G., et al. In vivo targeting of DC-SIGN-positive antigen-presenting cells in a nonhuman primate model. J Immunother 2007, 30:705-714.
37. Tacken P.J., de Vries I.J., Gijzen K., Joosten B., Wu D., Rother R.P., et al. Effective induction of naive and recall T cell responses by targeting antigen to human dendritic cells via a humanized anti-DC-SIGN antibody. Blood 2005, 106:1278-1285.
38. Tacken P.J., Joosten B., Reddy A., Wu D., Eek A., Laverman P., et al. No advantage of cell-penetrating peptides over receptor-specific antibodies in targeting antigen to human dendritic cells for cross-presentation. J Immunol 2008, 180:7687-7696.
39. Angel C.E., Chen C.J., Horlacher O.C., Winkler S., John T., Browning J., et al. Distinctive localization of antigen-presenting cells in human lymph nodes. Blood 2009, 113:1257-1267.
40. + counterparts. Int Immunol 2007, 19:1271-1279.
41. + dermal dendritic cells. Immunity 2008, 29:497-510.
42. Ebner S., Ehammer Z., Holzmann S., Schwingshackl P., Forstner M., Stoitzner P., et al. Expression of C-type lectin receptors by subsets of dendritic cells in human skin. Int Immunol 2004, 16:877-887.
43. Engering A., van Vliet S.J., Hebeda K., Jackson D.G., Prevo R., Singh S.K., et al. Dynamic populations of dendritic cell-specific ICAM-3 grabbing nonintegrin-positive immature dendritic cells and liver/lymph node-specific ICAM-3 grabbing nonintegrin-positive endothelial cells in the outer zones of the paracortex of human lymph nodes. Am J Pathol 2004, 164:1587-1595.
44. Granelli-Piperno A., Pritsker A., Pack M., Shimeliovich I., Arrighi J.F., Park C.G., et al. Dendritic cell-specific intercellular adhesion molecule 3-grabbing nonintegrin/CD209 is abundant on macrophages in the normal human lymph node and is not required for dendritic cell stimulation of the mixed leukocyte reaction. J Immunol 2005, 175:4265-4273.
45. Schwartz A.J., Alvarez X., Lackner A.A. Distribution and immunophenotype of DC-SIGN-expressing cells in SIV-infected and uninfected macaques. AIDS Res Hum Retroviruses 2002, 18:1021-1029.
46. Soilleux E.J., Morris L.S., Leslie G., Chehimi J., Luo Q., Levroney E., et al. Constitutive and induced expression of DC-SIGN on dendritic cell and macrophage subpopulations in situ and in vitro. J Leukoc Biol 2002, 71:445-457.
47. Tailleux L., Schwartz O., Herrmann J.L., Pivert E., Jackson M., Amara A., et al. DC-SIGN is the major Mycobacterium tuberculosis receptor on human dendritic cells. J Exp Med 2003, 197:121-127.
48. He L.Z., Crocker A., Lee J., Mendoza-Ramirez J., Wang X.T., Vitale L.A., et al. Antigenic targeting of the human mannose receptor induces tumor immunity. J Immunol 2007, 178:6259-6267.
49. Merad M., Manz M.G., Karsunky H., Wagers A., Peters W., Charo I., et al. Langerhans cells renew in the skin throughout life under steady-state conditions. Nat Immunol 2002, 3:1135-1141.
50. Romani N., Clausen B.E., Stoitzner P. Langerhans cells and more: Langerin-expressing dendritic cell subsets in the skin. Immunol Rev 2010, 234:120-141.
51. + hematopoietic progenitors stimulate greater cytolytic T lymphocyte activity in the absence of bioactive IL-12p70, by either single peptide presentation or cross-priming, than do dermal-interstitial or monocyte-derived dendritic cells. J Immunol 2004, 173:2780-2791.
52. Stoitzner P., Green L.K., Jung J.Y., Price K.M., Tripp C.H., Malissen B., et al. Tumor immunotherapy by epicutaneous immunization requires Langerhans cells. J Immunol 2008, 180:1991-1998.
53. Flacher V., Tripp C.H., Stoitzner P., Haid B., Ebner S., Del F.B., et al. Epidermal Langerhans cells rapidly capture and present antigens from C-type lectin-targeting antibodies deposited in the dermis. J Invest Dermatol 2010, 130:755-762.
54. Burgdorf S., Kautz A., Bohnert V., Knolle P.A., Kurts C. Distinct pathways of antigen uptake and intracellular routing in CD4 and CD8 T cell activation. Science 2007, 316:612-616.
55. Herre J., Marshall A.S., Caron E., Edwards A.D., Williams D.L., Schweighoffer E., et al. Dectin-1 uses novel mechanisms for yeast phagocytosis in macrophages. Blood 2004, 104:4038-4045.
56. Geijtenbeek T.B.H., Gringhuis S.I. Signalling through C-type lectin receptors: shaping immune responses. Nat Rev Immunol 2009, 9:465-479.
57. Hodges A., Sharrocks K., Edelmann M., Baban D., Moris A., Schwartz O., et al. Activation of the lectin DC-SIGN induces an immature dendritic cell phenotype triggering Rho-GTPase activity required for HIV-1 replication. Nat Immunol 2007, 8:569-577.
58. Chieppa M., Bianchi G., Doni A., Del Prete A., Sironi M., Laskarin G., et al. Cross-linking of the mannose receptor on monocyte-derived dendritic cells activates an anti-inflammatory immunosuppressive program. J Immunol 2003, 171:4552-4560.
59. Speiser D.E., Romero P. Molecularly defined vaccines for cancer immunotherapy, and protective T cell immunity. Semin Immunol 2010, 22:144-154.
60. Kool M., Soullie T., van Nimwegen M., Willart M.A., Muskens F., Jung S., et al. Alum adjuvant boosts adaptive immunity by inducing uric acid and activating inflammatory dendritic cells. J Exp Med 2008, 205:869-882.
61. Kool M., Petrilli V., De S.T., Rolaz A., Hammad H., van Nimwegen M., et al. Cutting edge: alum adjuvant stimulates inflammatory dendritic cells through activation of the NALP3 inflammasome. J Immunol 2008, 181:3755-3759.
62. Eisenbarth S.C., Colegio O.R., 'Connor W., Sutterwala F.S., Flavell R.A. Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants. Nature 2008, 453:1122-1126.
63. Cluff C.W. Monophosphoryl lipid A (MPL) as an adjuvant for anti-cancer vaccines: clinical results. Adv Exp Med Biol 2009, 667:111-123.
64. van M.N., Camps M.G., Khan S., Filippov D.V., Weterings J.J., Griffith J.M., et al. Antigen storage compartments in mature dendritic cells facilitate prolonged cytotoxic T lymphocyte cross-priming capacity. Proc Natl Acad Sci USA 2009, 106:6730-6735.
65. Dubensky T.W., Reed S.G. Adjuvants for cancer vaccines. Semin Immunol 2010, 22:155-161.
66. Steinman R.M., Banchereau J. Taking dendritic cells into medicine. Nature 2007, 449:419-426.
67. + T cell tolerance. J Exp Med 2002, 196:1627-1638.
68. Hawiger D., Inaba K., Dorsett Y., Guo M., Mahnke K., Rivera M., et al. Dendritic cells induce peripheral T cell unresponsiveness under steady state conditions in vivo. J Exp Med 2001, 194:769-779.
69. Mahnke K., Qian Y.J., Knop J., Enk A.H. Induction of CD4(+)/CD25(+) regulatory T cells by targeting of antigens to immature dendritic cells. Blood 2003, 101:4862-4869.
70. + dendritic cells. J Immunol 2008, 180:3201-3209.
71. de Vries I.J., Lesterhuis W.J., Scharenborg N.M., Engelen L.P., Ruiter D.J., Gerritsen M.J., et al. Maturation of dendritic cells is a prerequisite for inducing immune responses in advanced melanoma patients. Clin Cancer Res 2003, 9:5091-5100.
72. Dhodapkar M.V., Steinman R.M., Krasovsky J., Munz C., Bhardwaj N. Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells. J Exp Med 2001, 193:233-238.
73. + T cell responses through in vivo targeting of antigen to dendritic cell-associated C-type lectin-1. J Immunol 2006, 177:2276-2284.
74. Lahoud M.H., Proietto A.I., Ahmet F., Kitsoulis S., Eidsmo L., Wu L., et al. The C-type lectin Clec12A present on mouse and human dendritic cells can serve as a target for antigen delivery and enhancement of antibody responses. J Immunol 2009, 182:7587-7594.
75. + Th1 immunity with poly IC as adjuvant. J Exp Med 2009, 206:1589-1602.
76. Quezada S.A., Jarvinen L.Z., Lind E.F., Noelle R.J. CD40/CD154 interactions at the interface of tolerance and immunity. Annu Rev Immunol 2004, 22:307-328.
77. Zhang L., Tang Y., Akbulut H., Zelterman D., Linton P.J., Deisseroth A.B. An adenoviral vector cancer vaccine that delivers a tumor-associated antigen/CD40-ligand fusion protein to dendritic cells. Proc Natl Acad Sci USA 2003, 100:15101-15106.
78. De Gruijl T.D., Luykx-de Bakker S.A., Tillman B.W., van den Eertwegh A.J., Buter J., Lougheed S.M., et al. Prolonged maturation and enhanced transduction of dendritic cells migrated from human skin explants after in situ delivery of CD40-targeted adenoviral vectors. J Immunol 2002, 169:5322-5331.
79. Tillman B.W., De Gruijl T.D., Luykx-de Bakker S.A., Scheper R.J., Pinedo H.M., Curiel T.J., et al. Maturation of dendritic cells accompanies high-efficiency gene transfer by a CD40-targeted adenoviral vector. J Immunol 1999, 162:6378-6383.
80. Bonifaz L.C., Bonnyay D.P., Charalambous A., Darguste D.I., Fujii S., Soares H., et al. In vivo targeting of antigens to maturing dendritic cells via the DEC-205 receptor improves T cell vaccination. J Exp Med 2004, 199:815-824.
81. He L.Z., Ramakrishna V., Connolly J.E., Wang X.T., Smith P.A., Jones C.L., et al. A novel human cancer vaccine elicits cellular responses to the tumor-associated antigen, human chorionic gonadotropin b. Clin Cancer Res 2004, 10:1920-1927.
82. Weiner L.M., Surana R., Wang S. Monoclonal antibodies: versatile platforms for cancer immunotherapy. Nat Rev Immunol 2010, 10:317-327.
83. Watts C., West M.A., Zaru R. TLR signalling regulated antigen presentation in dendritic cells. Curr Opin Immunol 2010, 22:124-130.
84. Fujii S., Takayama T., Asakura M., Aki K., Fujimoto K., Shimizu K. Dendritic cell-based cancer immunotherapies. Arch Immunol Ther Exp 2009, 57:189-198.
85. Levy H.B., Baer G., Baron S., Buckler C.E., Gibbs C.J., Iadarola M.J., et al. A modified polyriboinosinic-polyribocytidylic acid complex that induces interferon in primates. J Infect Dis 1975, 132:434-439.
86. Okada H. Brain tumor immunotherapy with type-1 polarizing strategies. Ann N Y Acad Sci 2009, 1174:18-23.
87. Schon M.P., Schon M. TLR7 and TLR8 as targets in cancer therapy. Oncogene 2008, 27:190-199.
88. Kanneganti T.D., Ozoren N., Body-Malapel M., Amer A., Park J.H., Franchi L., et al. Bacterial RNA and small antiviral compounds activate caspase-1 through cryopyrin/Nalp3. Nature 2006, 440:233-236.
89. Hemmi H., Kaisho T., Takeuchi O., Sato S., Sanjo H., Hoshino K., et al. Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat Immunol 2002, 3:196-200.
90. Jurk M., Heil F., Vollmer J., Schetter C., Krieg A.M., Wagner H., et al. Human TLR7 or TLR8 independently confer responsiveness to the antiviral compound R-848. Nat Immunol 2002, 3:499.
91. Gorden K.B., Gorski K.S., Gibson S.J., Kedl R.M., Kieper W.C., Qiu X., et al. Synthetic TLR agonists reveal functional differences between human TLR7 and TLR8. J Immunol 2005, 174:1259-1268.
92. Wille-Reece U., Flynn B.J., Lore K., Koup R.A., Miles A.P., Saul A., et al. Toll-like receptor agonists influence the magnitude and quality of memory T cell responses after prime-boost immunization in nonhuman primates. J Exp Med 2006, 203:1249-1258.
93. + T cell responses in nonhuman primates. Proc Natl Acad Sci USA 2005, 102:15190-15194.
94. + T cell responses. J Immunol 2005, 174:7676-7683.
95. + T cells by targeting antigens to human dendritic cells through DCIR. Blood 2010, DOI:10.1182.
96. Ramakrishna V., Vasilakos J., Tario J., Berger M., Wallace P., Keler T. Toll-like receptor activation enhances cell-mediated immunity induced by an antibody vaccine targeting human dendritic cells. J Transl Med 2007, 5:5.
97. Napolitani G., Rinaldi A., Bertoni F., Sallusto F., Lanzavecchia A. Selected toll-like receptor agonist combinations synergistically trigger a T helper type 1-polarizing program in dendritic cells. Nat Immunol 2005, 6:769-776.
98. + T cell immunity in mice with anti-dendritic cell HIV gag fusion antibody vaccine. J Exp Med 2006, 203:607-617.
99. Lampkin B.C., Levine A.S., Levy H., Krivit W., Hammond D. Phase II trial of a complex polyriboinosinic-polyribocytidylic acid with poly-l-lysine and carboxymethyl cellulose in the treatment of children with acute leukemia and neuroblastoma: a report from the Children's Cancer Study Group. Cancer Res 1985, 45:5904-5909.
100. Pockros P.J., Guyader D., Patton H., Tong M.J., Wright T., McHutchison J.G., et al. Oral resiquimod in chronic HCV infection: safety and efficacy in 2 placebo-controlled, double-blind phase IIa studies. J Hepatol 2007, 47:174-182.
101. Blander J.M., Medzhitov R. Toll-dependent selection of microbial antigens for presentation by dendritic cells. Nature 2006, 440:808-812.
102. Burgdorf S., Scholz C., Kautz A., Tampe R., Kurts C. Spatial and mechanistic separation of cross-presentation and endogenous antigen presentation. Nat Immunol 2008, 9:558-566.
103. Nierkens S., den Brok M.H., Sutmuller R.P.M., Grauer O.M., Bennink E., Morgan M.E., et al. In vivo colocalization of antigen and cytidyl guanosyl within dendritic cells is associated with the efficacy of cancer immunotherapy. Cancer Res 2008, 68:5390-5396.
104. Schlosser E., Mueller M., Fischer S., Basta S., Busch D.H., Gander B., et al. TLR ligands and antigen need to be coencapsulated into the same biodegradable microsphere for the generation of potent cytotoxic T lymphocyte responses. Vaccine 2008, 26:1626-1637.
105. Khan S., Bijker M.S., Weterings J.J., Tanke H.J., Adema G.J., van H.T., et al. Distinct uptake mechanisms but similar intracellular processing of two different toll-like receptor ligand-peptide conjugates in dendritic cells. J Biol Chem 2007, 282:21145-21159.
106. Reddy S.T., van der Vlies A.J., Simeoni E., Angeli V., Randolph G.J., O'Neil C.P., et al. Exploiting lymphatic transport and complement activation in nanoparticle vaccines. Nat Biotech 2007, 25:1159-1164.
107. Manolova V., Flace A., Bauer M., Schwarz K., Saudan P., Bachmann M.F. Nanoparticles target distinct dendritic cell populations according to their size. Eur J Immunol 2008, 38:1404-1413.
108. Cruz L.J., Tacken P.J., Fokkink R., Joosten B., Stuart M.C., Albericio F., et al. Targeted PLGA nano- but not microparticles specifically deliver antigen to human dendritic cells via DC-SIGN in vitro. J Control Release 2010, 144:118-126.
109. van Broekhoven C.L., Parish C.R., Demangel C., Britton W.J., Altin J.G. Targeting dendritic cells with antigen-containing liposomes: a highly effective procedure for induction of antitumor immunity and for tumor immunotherapy. Cancer Res 2004, 64:4357-4365.
110. Palucka A.K., Ueno H., Fay J., Banchereau J. Dendritic cells: a critical player in cancer therapy?. J Immunother 2008, 31:793-805.
111. + T cells in a spectrum of human MHC I haplotypes. Proc Natl Acad Sci USA 2007, 104:1289-1294.
112. Ramakrishna V., Treml J.F., Vitale L., Connolly J.E., O'Neill T., Smith P.A., et al. Mannose receptor targeting of tumor antigen pmel17 to human dendritic cells directs anti-melanoma T cell responses via multiple HLA molecules. J Immunol 2004, 172:2845-2852.
113. Birkholz K., Schwenkert M., Kellner C., Gross S., Fey G., Schuler-Thurner B., et al. Targeting of DEC-205 on human dendritic cells results in efficient MHC class II-restricted antigen presentation. Blood 2010, DOI:10.1182.
114. Gavin A.L., Hoebe K., Duong B., Ota T., Martin C., Beutler B., et al. Adjuvant-enhanced antibody responses in the absence of toll-like receptor signaling. Science 2006, 314:1936-1938.
115. Sharp F.A., Ruane D., Claass B., Creagh E., Harris J., Malyala P., et al. Uptake of particulate vaccine adjuvants by dendritic cells activates the NALP3 inflammasome. Proc Natl Acad Sci USA 2009, 106:870-875.
116. Schnare M., Barton G.M., Holt A.C., Takeda K., Akira S., Medzhitov R. Toll-like receptors control activation of adaptive immune responses. Nat Immunol 2001, 2:947-950.
117. Schreibelt G., Benitez-Ribas D., Schuurhuis D., Lambeck A.J.A., van Hout-Kuijer M., Schaft N., et al. Commonly used prophylactic vaccines as an alternative for synthetically produced TLR ligands to mature monocyte-derived dendritic cells. Blood 2010, 116:564-574.
118. + macrophages. J Invest Dermatol 2008, 128:2225-2231.
119. Turville S.G., Cameron P.U., Handley A., Lin G., Pohlmann S., Doms R.W., et al. Diversity of receptors binding HIV on dendritic cell subsets. Nat Immunol 2002, 3:975-983.
120. + macrophages. J Clin Invest 2007, 117:2517-2525.
121. + dendritic cells. J Exp Med 2007, 204:3147-3156.
122. + dendritic cells survey the skin in the steady state. J Exp Med 2007, 204:3133-3146.
123. + dendritic cells that develop and function independently of epidermal Langerhans cells. J Exp Med 2007, 204:3119-3131.
124. Carayanniotis G., Barber B.H. Adjuvant-free IgG responses induced with antigen coupled to antibodies against class II MHC. Nature 1987, 327:59-61.
125. Mahnke K., Guo M., Lee S., Sepulveda H., Swain S.L., Nussenzweig M., et al. The dendritic cell receptor for endocytosis DEC-205, can recycle and enhance antigen presentation via major histocompatibility complex class II-positive lysosomal compartments. J Cell Biol 2000, 151:673-684.